A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease
Latest Information Update: 30 Mar 2025
At a glance
- Drugs Melatonin/tetrahydrocannabinol (Primary) ; Melatonin/tetrahydrocannabinol (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- Acronyms CALMA; IGC-AD1-P2
- Sponsors India Globalization Capital
Most Recent Events
- 25 Nov 2024 Interim results published in the IGC Pharma Media Release
- 16 Apr 2024 Interim Results demonstrating a clinically significant reduction, approaching statistical significance, in agitation in Alzheimers at week two compared to placebo, published in the IGC Pharma Inc. media release.
- 09 Apr 2024 According to an IGC Pharma Inc. media release, Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma's lead therapeutic candidate targeting agitation in Alzheimer's disease.